Table 3. Univariate and multivariable analysis of predictors of PFS in patients treated with first-line therapy for locally advanced or metastatic NSCLC.
| Evaluated variables | Univariate Cox regression | Multivariable Cox regression | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (≥70 vs. <70 years) | 1.08 (0.85−1.35) | 0.568 | |||
| Gender (F vs. M) | 0.82 (0.64−1.06) | 0.131 | 1.03 | 0.854 | |
| ECOG-PS (≥2 vs. <2) | 1.18 (0.77−1.82) | 0.451 | |||
| Smoke status (Y vs. N) | 1.15 (0.85−1.56) | 0.377 | |||
| Tumor stage (IV vs. III) | 1.19 (0.93−1.53) | 0.168 | 0.99 | 0.987 | |
| Histology (non-AC vs. AC) | 1.00 (0.82−1.21) | 0.983 | |||
| EGFR status (WT vs. MT) | 0.52 (0.34−0.79) | 0.002 | 0.54 | 0.006 | |
| SII (≥1,270 vs. <1,270) | 1.32 (1.05−1.67) | 0.020 | 1.48 | 0.026 | |
Y, yes; N, no; AC, adenocarcinoma; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; EGFR, epidermal growth factor receptor; F, female; HR, hazard ratio; M, male; MT, mutated status; NLR, neutrophil to lymphocyte ratio; WT, wild-type status; NSCLC, non-small cell lung cancer; PFS, progression free survival.